Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/72734
DC FieldValueLanguage
dc.contributor.authorZozaya, Neboaen_US
dc.contributor.authorAlcala, Blericen_US
dc.contributor.authorGalindo, Jhonen_US
dc.date.accessioned2020-05-22T09:45:38Z-
dc.date.available2020-05-22T09:45:38Z-
dc.date.issued2019en_US
dc.identifier.issn2284-2403en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/72734-
dc.description.abstractIt is well known that pharmaceutical innovation has improved the health and quality of life of patients. It is however sometimes forgotten that new drugs also have the potential of improving the efficiency and the sustainability of the healthcare system. The objective of this review is to shed light on the magnitude of the offset effect that drugs may have in the realm of the healthcare system and for society as a whole. A narrative literature review was carried out. This review demonstrated that a growing body of literature has tried to measure the magnitude of the offset effect associated with pharmaceutical innovation, both at the aggregate level and for different diseases. There is evidence that the aggregate use of new drugs can generate net savings to the healthcare system and to society, as they may release both healthcare and non-healthcare resources for alternative uses. A high degree of heterogeneity in the magnitude of the effect has been found across different pathologies and different types of drugs.en_US
dc.languageengen_US
dc.relation.ispartofGlobal and Regional Health Technology Assessmenten_US
dc.sourceGlobal & Regional Health Technology Assessment [ISSN 2284-2403], v. 2019, (Septiembre 2019)en_US
dc.subject3209 Farmacologíaen_US
dc.subject.otherInsulin Pen Therapyen_US
dc.subject.otherHealth-Care Costsen_US
dc.subject.otherMedication Adherenceen_US
dc.subject.otherEconomic-Evaluationen_US
dc.subject.otherUnited-Statesen_US
dc.subject.otherChildhood Immunizationen_US
dc.subject.otherCardiovascular Drugsen_US
dc.subject.otherVaccination Programsen_US
dc.subject.otherAsthma Controlen_US
dc.subject.otherImpacten_US
dc.subject.otherPharmaceutical Innovationen_US
dc.subject.otherDrugsen_US
dc.subject.otherOffset Effecten_US
dc.subject.otherSavingsen_US
dc.subject.otherCostsen_US
dc.subject.otherEconomic Impacten_US
dc.titleThe offset effect of pharmaceutical innovation: A review studyen_US
dc.typeinfo:eu-repo/semantics/reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.1177/2284240319875108-
dc.identifier.isi000486501700001-
dc.identifier.eissn2283-5733-
dc.relation.volume2019en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Reseñaen_US
dc.contributor.daisngid7098471-
dc.contributor.daisngid22208313-
dc.contributor.daisngid4878432-
dc.description.numberofpages10en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Zozaya, N-
dc.contributor.wosstandardWOS:Alcala, B-
dc.contributor.wosstandardWOS:Galindo, J-
dc.date.coverdateSeptiembre 2019en_US
item.grantfulltextopen-
item.fulltextCon texto completo-
Appears in Collections:Reseña
Adobe PDF (246,17 kB)
Show simple item record

Page view(s)

6
checked on May 23, 2020

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.